| abstract |
Pharmaceutical composition comprising an alpha-MSH analog selected from the group consisting of: [Nle4, D-Phe7] -alpha MSH [Nle4, D-Phe7] -alpha MSH4-10 [Nle4, D-Phe7] -alpha MSH4- 11 [Nle4, D-Phe7-D-Trp9] -alpha MSH4-11, or [Nle4, D-Phe7] -alpha MSH4-9 for use in the treatment or prevention of vitiligo in a human subject where the pharmaceutical composition is administered subcutaneously in a sustained release delivery system. |